Mineralys Therapeutics Announced JAMA Publication Of Full Target-HTN Phase 2 Trial Results for Lorundrostat In Uncontrolled and Treatment-Resistant Hypertension
Portfolio Pulse from Charles Gross
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced the publication of full results from the Target-HTN Phase 2 trial of lorundrostat in the Journal of the American Medical Association. The trial showed a robust, double-digit reduction in systolic blood pressure with a well-tolerated profile, especially in individuals with elevated body mass index. The results led to lorundrostat being the first of a new class, aldosterone synthase inhibitors, to start a pivotal clinical program in hypertension.
September 10, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the Phase 2 trial of lorundrostat could boost investor confidence in Mineralys Therapeutics, potentially leading to a short-term increase in the company's stock price.
The publication of positive Phase 2 trial results in a prestigious medical journal like JAMA is a significant milestone for Mineralys Therapeutics. This could increase investor confidence in the company's ability to develop effective treatments, potentially leading to increased demand for the company's stock and a short-term increase in its price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100